24-LUN-140-DS-PMC (DS3201-330): A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial of Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Whose

Grants and Contracts Details

StatusActive
Effective start/end date11/12/2411/12/26

Funding

  • Daiichi Sankyo Incorporated: $2.00